Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05543629 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT05543629 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 36 participants.
The verdict
NCT05543629, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- BIOLOGICAL Nivolumab
- BIOLOGICAL BMS-986442
- DRUG Pemexetred
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-10-04 |
| Est. Completion | 2024-09-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05543629
The ClinicalTrials.gov registry entry for NCT05543629 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT05543629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05543629 about?
NCT05543629 is a clinical study titled "A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer". The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.
What is the current status of trial NCT05543629?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-10-04. Estimated completion is 2024-09-12.
What interventions are being tested in trial NCT05543629?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Nivolumab (BIOLOGICAL), BMS-986442 (BIOLOGICAL), Pemexetred (DRUG).
Who is sponsoring clinical trial NCT05543629?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.